ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this phase II trial is to determine the efficacy and safety of
ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent
high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation
sensitizes to oral administration of ONC201 in gliomas.